Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892288 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
A Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG, sponsored by Glycomine.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06892288 is a Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG that is active but no longer recruiting, run by Glycomine. The registered enrollment target is 50 participants. The trial reports 15 study locations across 5 states.
The verdict
NCT06892288, a Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG, is active but no longer recruiting, sponsored by Glycomine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).
Conditions Studied
Interventions
- DRUG GLM101 (Part A, Double-blind)
- DRUG Placebo (Part A, Double-blind)
- DRUG GLM101 (Part B, Open-label)
Study Locations (15)
Other
- UZ Leuven, Campus Gasthuisberg - Leuven
- Vseobecna fakultni nemocnice v Praze - Prague
- AP-HP Hopital Necker-Enfants Malades - Paris
- Universitaetsklinikum Muenster - Münster
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Catania
- Azienda Ospedaliero Universitaria Pisana - Pisa
- Instytut Matki i Dziecka - Warsaw
- Unidade Local de Saúde de Santo António - Porto
- Hospital Sant Joan de Déu - Esplugues de Llobregat
- Hospital Universitario 12 de Octubre - Madrid
- Birmingham Women's and Children's NHS Foundation Trust - Birmingham
Minnesota
- University of Minnesota - Minneapolis
New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06892288
The ClinicalTrials.gov registry entry for NCT06892288 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glycomine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Phosphomannomutase 2 Deficiency appearing as the primary indexed condition, and to 3 interventions - of which GLM101 (Part A, Double-blind) is the first listed.
NCT06892288 reports 15 study locations spanning 5 distinct geographic areas - top geographies include Other, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06892288 about?
NCT06892288 is a clinical study titled "A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG". This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves...
What is the current status of trial NCT06892288?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-07-09. Estimated completion is 2027-04-30.
What conditions does trial NCT06892288 study?
This clinical trial studies the following conditions: Phosphomannomutase 2 Deficiency, PMM2-CDG.
What interventions are being tested in trial NCT06892288?
The interventions under investigation include: GLM101 (Part A, Double-blind) (DRUG), Placebo (Part A, Double-blind) (DRUG), GLM101 (Part B, Open-label) (DRUG).
Who is sponsoring clinical trial NCT06892288?
This trial is sponsored by Glycomine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892288 being conducted?
This trial has 15 study locations across Minnesota, New York, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phosphomannomutase 2 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.